Kokkali Stefania, Tripodaki Elli-Sophia, Drizou Maria, Stefanou Dimitra, Magou Elpida, Zylis Dimosthenis, Kapiris Matthaios, Nasi Despoina, Georganta Chara, Ardavanis Alexandros
First Medical Oncology Clinic, Saint Savvas Anticancer Hospital, Athens, Greece
First Medical Oncology Clinic, Saint Savvas Anticancer Hospital, Athens, Greece.
In Vivo. 2018 May-Jun;32(3):653-657. doi: 10.21873/invivo.11289.
BACKGROUND/AIM: During recent years, a survival advantage was reported for first-line treatment of advanced pancreatic cancer with two new regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel, over gemcitabine monotherapy. Gemcitabine/nab-paclitaxel administration on days 1, 8 and 15 of a 4-week cycle is associated with some practical disadvantages. We adopted a biweekly regimen with the same dose density.
Patients with Eastern Cooperative Oncology Group performance status 0-2 diagnosed with advanced histologically or cytologically confirmed pancreatic cancer and no prior treatment were included in the study. Study combination included 1.5 g/m gemcitabine and 175 mg/m nab-paclitaxel given every 2 weeks. Survival analysis was performed using the Kaplan-Meier method.
Forty-six patients were treated with this regimen. Adverse events were similar to those of the original regimen. Median progression-free and overall survival were 5 and 10 months, respectively.
Biweekly gemcitabine/nab-paclitaxel seems to have a similar safety and efficacy profile as the original regimen.
背景/目的：近年来，有报道称，与吉西他滨单药治疗相比，两种新方案FOLFIRINOX和吉西他滨/纳米白蛋白结合型紫杉醇用于晚期胰腺癌一线治疗具有生存优势。在4周周期的第1、8和15天给予吉西他滨/纳米白蛋白结合型紫杉醇存在一些实际缺点。我们采用了具有相同剂量密度的双周方案。
研究纳入了东部肿瘤协作组体能状态为0 - 2、经组织学或细胞学确诊为晚期胰腺癌且未接受过先前治疗的患者。研究联合用药方案为每2周给予1.5 g/m²吉西他滨和175 mg/m²纳米白蛋白结合型紫杉醇。采用Kaplan-Meier法进行生存分析。
46例患者接受了该方案治疗。不良事件与原方案相似。中位无进展生存期和总生存期分别为5个月和10个月。
双周给药的吉西他滨/纳米白蛋白结合型紫杉醇似乎与原方案具有相似的安全性和疗效。
